Patents by Inventor Kerry David Fisher
Kerry David Fisher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938159Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: GrantFiled: December 23, 2020Date of Patent: March 26, 2024Assignee: AKAMIS BIO LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Patent number: 11439678Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: GrantFiled: April 30, 2018Date of Patent: September 13, 2022Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Publication number: 20210187047Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: ApplicationFiled: December 23, 2020Publication date: June 24, 2021Inventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Publication number: 20190233536Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engager (BiTE™) each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.Type: ApplicationFiled: August 29, 2017Publication date: August 1, 2019Inventors: Brian Robert CHAMPION, Alice Claire Noel BROMLEY, Joshua David FREEDMAN, Kerry David FISHER, Leonard William SEYMOUR
-
Publication number: 20190194690Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE™) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.Type: ApplicationFiled: August 29, 2017Publication date: June 27, 2019Inventors: Brian Robert CHAMPION, Alice Claire Noel BROMLEY, Joshua David FREEDMAN, Kerry David FISHER, Leonard William SEYMOUR
-
Publication number: 20180311291Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: ApplicationFiled: April 30, 2018Publication date: November 1, 2018Inventors: Brian Robert CHAMPION, Alice Claire Noel BROWN, Kerry David FISHER, Tamara NICOLSON
-
Patent number: 9987314Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BAB2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: GrantFiled: October 24, 2014Date of Patent: June 5, 2018Assignee: Psioxus Therapeutics LimitedInventors: Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
-
Publication number: 20170073647Abstract: The present disclosure relates to a process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Ad11, in particular Ad11p also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps: a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step. The disclosure also extends to formulations and viruses obtained from the process.Type: ApplicationFiled: February 27, 2015Publication date: March 16, 2017Inventors: Kerry David FISHER, Brian Robert CHAMPION, Jeetendra BHATIA
-
Publication number: 20160331793Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BAB2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.Type: ApplicationFiled: October 24, 2014Publication date: November 17, 2016Inventors: Brian Robert CHAMPION, Alice Claire Noel BROWN, Kerry David FISHER, Tamara NICOLSON
-
Patent number: 7279318Abstract: A method of modifying the biological and/or physicochemical properties of biological elements such as viruses and other micro-organisms is disclosed in which the biological element is modified by providing it with a coating of a multivalent polymer having multiple reactive groups. This modification can enable some biological elements to be targeted or re-targeted to particular sites in a host biological system and can be useful in connection with viral vectors for gene therapy or antitumor therapy. In other cases the modification can be useful for enhancing or improving the efficiency of viruses or bacterial micro-organisms used for example in pest control, degradation and dispersal of oil deposits and various other industrial, environment or medical applications.Type: GrantFiled: June 9, 1999Date of Patent: October 9, 2007Assignee: Hybrid Systems LimitedInventors: Leonard C. W. Seymour, Kerry David Fisher